PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000075

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Identifieur interne : 000075 ( PascalFrancis/Corpus ); précédent : 000074; suivant : 000076

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Auteurs : Henning K. Olberg ; Rebecca J. Cox ; Jane K. Nostbakken ; Jan H. Aarseth ; Christian A. Vedeler ; Kjell-Morten Myhr

Source :

Multiple sclerosis [ 1352-4585 ] ; 2014.

RBID : Pascal:14-0174934

Descripteurs français

Pascal (Inist)
- Sclérose en plaques, Pathologie du système nerveux, Maladie dégénérative, Traitement, Immunothérapie, Grippe, Vaccination, Homme, Immunité, Facteur risque, Réponse multiple.

English descriptors

KwdEn :
- Degenerative disease, Human, Immunity, Immunotherapy, Influenza, Multiple sclerosis, Nervous system diseases, Risk factor, Treatment, Vaccination.

Abstract

Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic HINI (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic HINI vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 - 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic HINI vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1352-4585`
A03		`1`		`@0 Mult. scler.`
A05				`@2 20`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study`
A11	`01`	`1`		`@1 OLBERG (Henning K.)`
A11	`02`	`1`		`@1 COX (Rebecca J.)`
A11	`03`	`1`		`@1 NOSTBAKKEN (Jane K.)`
A11	`04`	`1`		`@1 AARSETH (Jan H.)`
A11	`05`	`1`		`@1 VEDELER (Christian A.)`
A11	`06`	`1`		`@1 MYHR (Kjell-Morten)`
A14	`01`			`@1 Department of Neurology, Haukeland University Hospital @2 Bergen @3 NOR @Z 1 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Research and Development, Haukeland University Hospital @2 Bergen @3 NOR @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Influenza Centre, Department of Clinical Science, University of Bergen @3 NOR @Z 2 aut. @Z 3 aut.`
A14	`04`			`@1 KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen @3 NOR @Z 2 aut.`
A14	`05`			`@1 Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital @2 Bergen @3 NOR @Z 4 aut. @Z 6 aut.`
A14	`06`			`@1 KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen @3 NOR @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`07`			`@1 Department of Clinical Medicine, University of Bergen @3 NOR @Z 5 aut.`
A14	`08`			`@1 Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital @2 Bergen @3 NOR @Z 6 aut.`
A20				`@1 1074-1080`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26577 @5 354000507624840090`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 14-0174934`
A60				`@1 P @3 PR`
A61				`@0 A`
A64	`01`	`1`		`@0 Multiple sclerosis`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic HINI (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic HINI vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 - 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic HINI vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B05C02C`
C02	`03`	`X`		`@0 002B17F`
C02	`04`	`X`		`@0 002B02Q`
C03	`01`	`X`	`FRE`	`@0 Sclérose en plaques @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Multiple sclerosis @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Esclerosis en placa @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 03`
C03	`03`	`X`	`ENG`	`@0 Degenerative disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 03`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`05`	`X`	`FRE`	`@0 Immunothérapie @5 10`
C03	`05`	`X`	`ENG`	`@0 Immunotherapy @5 10`
C03	`05`	`X`	`SPA`	`@0 Inmunoterapia @5 10`
C03	`06`	`X`	`FRE`	`@0 Grippe @5 11`
C03	`06`	`X`	`ENG`	`@0 Influenza @5 11`
C03	`06`	`X`	`SPA`	`@0 Gripe @5 11`
C03	`07`	`X`	`FRE`	`@0 Vaccination @5 12`
C03	`07`	`X`	`ENG`	`@0 Vaccination @5 12`
C03	`07`	`X`	`SPA`	`@0 Vacunación @5 12`
C03	`08`	`X`	`FRE`	`@0 Homme @5 13`
C03	`08`	`X`	`ENG`	`@0 Human @5 13`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 13`
C03	`09`	`X`	`FRE`	`@0 Immunité @5 14`
C03	`09`	`X`	`ENG`	`@0 Immunity @5 14`
C03	`09`	`X`	`SPA`	`@0 Inmunidad @5 14`
C03	`10`	`X`	`FRE`	`@0 Facteur risque @5 15`
C03	`10`	`X`	`ENG`	`@0 Risk factor @5 15`
C03	`10`	`X`	`SPA`	`@0 Factor riesgo @5 15`
C03	`11`	`X`	`FRE`	`@0 Réponse multiple @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Maladie inflammatoire @5 37`
C07	`03`	`X`	`ENG`	`@0 Inflammatory disease @5 37`
C07	`03`	`X`	`SPA`	`@0 Enfermedad inflamatoria @5 37`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 38`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
N21				`@1 216`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0174934 INIST
ET :	Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study
AU :	OLBERG (Henning K.); COX (Rebecca J.); NOSTBAKKEN (Jane K.); AARSETH (Jan H.); VEDELER (Christian A.); MYHR (Kjell-Morten)
AF :	Department of Neurology, Haukeland University Hospital/Bergen/Norvège (1 aut., 5 aut.); Department of Research and Development, Haukeland University Hospital/Bergen/Norvège (2 aut., 3 aut.); Influenza Centre, Department of Clinical Science, University of Bergen/Norvège (2 aut., 3 aut.); KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen/Norvège (2 aut.); Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital/Bergen/Norvège (4 aut., 6 aut.); KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen/Norvège (4 aut., 5 aut., 6 aut.); Department of Clinical Medicine, University of Bergen/Norvège (5 aut.); Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital/Bergen/Norvège (6 aut.)
DT :	Publication en série; Papier de recherche; Niveau analytique
SO :	Multiple sclerosis; ISSN 1352-4585; Royaume-Uni; Da. 2014; Vol. 20; No. 8; Pp. 1074-1080; Bibl. 17 ref.
LA :	Anglais
EA :	Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic HINI (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic HINI vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 - 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic HINI vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.
CC :	002B17G; 002B05C02C; 002B17F; 002B02Q
FD :	Sclérose en plaques; Pathologie du système nerveux; Maladie dégénérative; Traitement; Immunothérapie; Grippe; Vaccination; Homme; Immunité; Facteur risque; Réponse multiple
FG :	Virose; Infection; Maladie inflammatoire; Pathologie du système nerveux central
ED :	Multiple sclerosis; Nervous system diseases; Degenerative disease; Treatment; Immunotherapy; Influenza; Vaccination; Human; Immunity; Risk factor
EG :	Viral disease; Infection; Inflammatory disease; Central nervous system disease
SD :	Esclerosis en placa; Sistema nervioso patología; Enfermedad degenerativa; Tratamiento; Inmunoterapia; Gripe; Vacunación; Hombre; Inmunidad; Factor riesgo
LO :	INIST-26577.354000507624840090
ID :	14-0174934

Links to Exploration step

Pascal:14-0174934

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study</title>
<author><name sortKey="Olberg, Henning K" sort="Olberg, Henning K" uniqKey="Olberg H" first="Henning K." last="Olberg">Henning K. Olberg</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cox, Rebecca J" sort="Cox, Rebecca J" uniqKey="Cox R" first="Rebecca J." last="Cox">Rebecca J. Cox</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Research and Development, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Influenza Centre, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nostbakken, Jane K" sort="Nostbakken, Jane K" uniqKey="Nostbakken J" first="Jane K." last="Nostbakken">Jane K. Nostbakken</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Research and Development, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Influenza Centre, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Aarseth, Jan H" sort="Aarseth, Jan H" uniqKey="Aarseth J" first="Jan H." last="Aarseth">Jan H. Aarseth</name>
<affiliation><inist:fA14 i1="05"><s1>Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vedeler, Christian A" sort="Vedeler, Christian A" uniqKey="Vedeler C" first="Christian A." last="Vedeler">Christian A. Vedeler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Myhr, Kjell Morten" sort="Myhr, Kjell Morten" uniqKey="Myhr K" first="Kjell-Morten" last="Myhr">Kjell-Morten Myhr</name>
<affiliation><inist:fA14 i1="05"><s1>Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0174934</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0174934 INIST</idno>
<idno type="RBID">Pascal:14-0174934</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000075</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study</title>
<author><name sortKey="Olberg, Henning K" sort="Olberg, Henning K" uniqKey="Olberg H" first="Henning K." last="Olberg">Henning K. Olberg</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cox, Rebecca J" sort="Cox, Rebecca J" uniqKey="Cox R" first="Rebecca J." last="Cox">Rebecca J. Cox</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Research and Development, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Influenza Centre, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nostbakken, Jane K" sort="Nostbakken, Jane K" uniqKey="Nostbakken J" first="Jane K." last="Nostbakken">Jane K. Nostbakken</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Research and Development, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Influenza Centre, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Aarseth, Jan H" sort="Aarseth, Jan H" uniqKey="Aarseth J" first="Jan H." last="Aarseth">Jan H. Aarseth</name>
<affiliation><inist:fA14 i1="05"><s1>Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vedeler, Christian A" sort="Vedeler, Christian A" uniqKey="Vedeler C" first="Christian A." last="Vedeler">Christian A. Vedeler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Myhr, Kjell Morten" sort="Myhr, Kjell Morten" uniqKey="Myhr K" first="Kjell-Morten" last="Myhr">Kjell-Morten Myhr</name>
<affiliation><inist:fA14 i1="05"><s1>Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Multiple sclerosis</title>
<title level="j" type="abbreviated">Mult. scler.</title>
<idno type="ISSN">1352-4585</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Multiple sclerosis</title>
<title level="j" type="abbreviated">Mult. scler.</title>
<idno type="ISSN">1352-4585</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Degenerative disease</term>
<term>Human</term>
<term>Immunity</term>
<term>Immunotherapy</term>
<term>Influenza</term>
<term>Multiple sclerosis</term>
<term>Nervous system diseases</term>
<term>Risk factor</term>
<term>Treatment</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Sclérose en plaques</term>
<term>Pathologie du   système nerveux</term>
<term>Maladie dégénérative</term>
<term>Traitement</term>
<term>Immunothérapie</term>
<term>Grippe</term>
<term>Vaccination</term>
<term>Homme</term>
<term>Immunité</term>
<term>Facteur risque</term>
<term>Réponse multiple</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic HINI (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic HINI vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 - 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic HINI vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1352-4585</s0>
</fA01>
<fA03 i2="1"><s0>Mult. scler.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OLBERG (Henning K.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>COX (Rebecca J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>NOSTBAKKEN (Jane K.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AARSETH (Jan H.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>VEDELER (Christian A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MYHR (Kjell-Morten)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Research and Development, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Influenza Centre, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen</s1>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Clinical Medicine, University of Bergen</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>1074-1080</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26577</s2>
<s5>354000507624840090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0174934</s0>
</fA47>
<fA60><s1>P</s1>
<s3>PR</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Multiple sclerosis</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic HINI (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic HINI vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 - 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic HINI vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC02 i1="04" i2="X"><s0>002B02Q</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Sclérose en plaques</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Multiple sclerosis</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Esclerosis en placa</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunothérapie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunotherapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunoterapia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Grippe</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Influenza</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Gripe</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Immunité</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunity</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inmunidad</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Réponse multiple</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie inflammatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Inflammatory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad inflamatoria</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>216</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0174934 INIST</NO>
<ET>Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study</ET>
<AU>OLBERG (Henning K.); COX (Rebecca J.); NOSTBAKKEN (Jane K.); AARSETH (Jan H.); VEDELER (Christian A.); MYHR (Kjell-Morten)</AU>
<AF>Department of Neurology, Haukeland University Hospital/Bergen/Norvège (1 aut., 5 aut.); Department of Research and Development, Haukeland University Hospital/Bergen/Norvège (2 aut., 3 aut.); Influenza Centre, Department of Clinical Science, University of Bergen/Norvège (2 aut., 3 aut.); KG Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen/Norvège (2 aut.); Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital/Bergen/Norvège (4 aut., 6 aut.); KG Jebsen Centre for MS-Research, Department of Clinical Medicine, University of Bergen/Norvège (4 aut., 5 aut., 6 aut.); Department of Clinical Medicine, University of Bergen/Norvège (5 aut.); Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital/Bergen/Norvège (6 aut.)</AF>
<DT>Publication en série; Papier de recherche; Niveau analytique</DT>
<SO>Multiple sclerosis; ISSN 1352-4585; Royaume-Uni; Da. 2014; Vol. 20; No. 8; Pp. 1074-1080; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Background: The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied. Objectives: This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic HINI (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010. Methods: We investigated the immune response to pandemic HINI vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 - 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay. Results: MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic HINI vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010. Conclusions: These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.</EA>
<CC>002B17G; 002B05C02C; 002B17F; 002B02Q</CC>
<FD>Sclérose en plaques; Pathologie du   système nerveux; Maladie dégénérative; Traitement; Immunothérapie; Grippe; Vaccination; Homme; Immunité; Facteur risque; Réponse multiple</FD>
<FG>Virose; Infection; Maladie inflammatoire; Pathologie du système nerveux central</FG>
<ED>Multiple sclerosis; Nervous system diseases; Degenerative disease; Treatment; Immunotherapy; Influenza; Vaccination; Human; Immunity; Risk factor</ED>
<EG>Viral disease; Infection; Inflammatory disease; Central nervous system disease</EG>
<SD>Esclerosis en placa; Sistema nervioso patología; Enfermedad degenerativa; Tratamiento; Inmunoterapia; Gripe; Vacunación; Hombre; Inmunidad; Factor riesgo</SD>
<LO>INIST-26577.354000507624840090</LO>
<ID>14-0174934</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000075 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000075 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0174934
   |texte=   Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri